Department of Surgery, Henry Ford Cancer Institute, 2799 W Grand Boulevard, Detroit, MI, USA.
Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology, Zurich, Switzerland.
Clin Exp Metastasis. 2022 Feb;39(1):117-137. doi: 10.1007/s10585-021-10090-2. Epub 2021 May 5.
Invasive breast cancer tends to metastasize to lymph nodes and systemic sites. The management of metastasis has evolved by focusing on controlling the growth of the disease in the breast/chest wall, and at metastatic sites, initially by surgery alone, then by a combination of surgery with radiation, and later by adding systemic treatments in the form of chemotherapy, hormone manipulation, targeted therapy, immunotherapy and other treatments aimed at inhibiting the proliferation of cancer cells. It would be valuable for us to know how breast cancer metastasizes; such knowledge would likely encourage the development of therapies that focus on mechanisms of metastasis and might even allow us to avoid toxic therapies that are currently used for this disease. For example, if we had a drug that targeted a gene that is critical for metastasis, we might even be able to cure a vast majority of patients with breast cancer. By bringing together scientists with expertise in molecular aspects of breast cancer metastasis, and those with expertise in the mechanical aspects of metastasis, this paper probes interesting aspects of the metastasis cascade, further enlightening us in our efforts to improve the outcome from breast cancer treatments.
浸润性乳腺癌往往会转移到淋巴结和全身部位。转移性疾病的治疗方法不断发展,最初侧重于单独通过手术控制乳房/胸壁和转移部位的疾病生长,然后通过手术联合放疗,后来通过添加化疗、激素治疗、靶向治疗、免疫治疗等抑制癌细胞增殖的全身治疗形式。了解乳腺癌如何转移对我们来说将是有价值的;这种知识可能会鼓励开发专注于转移机制的治疗方法,甚至可能使我们能够避免目前用于治疗这种疾病的有毒疗法。例如,如果我们有一种针对转移关键基因的药物,我们甚至有可能治愈绝大多数乳腺癌患者。通过汇集在乳腺癌转移的分子方面具有专业知识的科学家,以及在转移的机械方面具有专业知识的科学家,本文探讨了转移级联的有趣方面,进一步启发我们努力改善乳腺癌治疗的结果。